Oncologist, Dr.Thomas Budd, also of Cleveland Clinic, will lead the clinical trial. Anixa Biosciences has an exclusive worldwide license to the technology. The technology immunizes against a protein called alpha-lactalbumin that is expressed in ...
“This initial clinical trial will be with women who have been diagnosed with high-risk early stage TNBC and are receiving standard of care at Cleveland Clinic,” said Dr. G. Thomas Budd, Department of Medical Oncology at the Taussig Cancer Center at Cleveland Clinic, and ...